This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (89)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Additive Effects on Plasma Cholesterol Concentrations in Patients With Familial Type II Hyperlipoproteinemia

Jacques LeLorier, MD, PhD, FRCP(C); Suzanne DuBreuil-Quidoz, RN; Suzanne Lussier-Cacan, MSc; Yung-Sheng Huang, PhD; Jean Davignon, MD, MSc, FRCP(C), FACP

Arch Intern Med. 1977;137(10):1429-1434.

Abstract
Probucol [4,4'-(isopropylidenedithio bis)(2,6-di-t-butylphenol)], as an adjunct to diet, was evaluated for its effect on lowering the plasma cholesterol level in patients with familial hypercholesterolemia (type II). The trial had a doubleblind, placebo-controlled, crossover design. About half of the 30 patients responded to a low-cholesterol modifiedfat diet with a decrease in the plasma cholesterol level of approximately 13%. When probucol was added to the diet of the responders, their plasma cholesterol level was lowered a further 13%. Patients who did not respond to the diet did show reduced plasma cholesterol concentrations when receiving probucol plus the diet. Analysis of the cholesterol content of the various lipoprotein fractions showed that the low-density lipoproteins accounted for most of the total plasma cholesterol level decrease.

There was, as expected, no effect on plasma triglyceride concentrations. Neither the 7-dehydrocholesterol nor the desmosterol level was increased in the plasma of patients treated with probucol for three months.

Probucol is useful as an adjunct to diet in lowering plasma cholesterol levels in patients with familial hypercholesterolemia. The drug was well tolerated by all patients.

(Arch Intern Med 137:1429-1434, 1977)

Author Affiliations
From the Clinical Research Institute of Montreal (Drs LeLorier, Huang, Davignon, and Ms DuBreuil-Quidoz and Lussier-Cacan), and the University of Montreal (Drs LeLorier and Davignon).

Footnotes
Accepted for publication June 7, 1977.

Reprint requests to Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal H2W 1R7, Quebec (Dr LeLorier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reducing High Blood Cholesterol Level With Drugs: Cost-effectiveness of Pharmacologic Management
Schulman et al.
JAMA 1990;264:3025-3033.
ABSTRACT  

Cholestyramine and Probucol Synergism
NESTEL
ANN INTERN MED 1982;97:622-622.
ABSTRACT  

The Mechanism of Action of Lipid-Lowering Drugs
LaRosa
ANGIOLOGY 1982;33:562-576.
 

Colestipol and Probucol: Treatment of Primary and Familial Hypercholesterolemia and Amelioration of Atherosclerosis
GLUECK
ANN INTERN MED 1982;96:475-482.
ABSTRACT  

The Long-term Effects of Probucol on Serum Lipid Levels
McCaughan
Arch Intern Med 1981;141:1428-1432.
ABSTRACT  

QT-Interval Prolongation Produced by Probucol
Klein
Arch Intern Med 1981;141:1102-1103.
ABSTRACT  

Probucol (Lorelco) in Treatment of Hyperlipemia
Murphy
JAMA 1977;238:2537-2538.
ABSTRACT